Cagrilintide: Dosage, CagriSema Results, and Research Guide

Cagrilintide is the compound that gets discussed alongside semaglutide and tirzepatide but works through a completely different pathway. Every major weight-loss agent of the past five years has been a GLP-1 receptor agonist or a multi-incretin approach layered on top of GLP-1. Cagrilintide is an amylin analogue, meaning it mimics a different pancreatic hormone entirely. It does not compete with semaglutide. It pairs with it.

That pairing is called CagriSema: a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg in a single weekly subcutaneous injection. The REDEFINE Phase 3 trial program positioned CagriSema against the best weight-loss numbers the GLP-1 class had produced, and the results were competitive with the top of that range. The research community is paying attention, and so are the people who have exhausted the current GLP-1 options and want to understand what comes next.

What cagrilintide actually does

Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells, in a roughly 1:100 molar ratio to insulin. Its job is to modulate what happens after a meal. It slows gastric emptying, which extends the window of food absorption and blunts the post-meal glucose spike. It acts on the area postrema and hypothalamus to signal satiety and reduce further food intake. And it suppresses glucagon secretion, which helps prevent the liver from releasing glucose when blood glucose is already elevated.

Native amylin has a problem as a therapeutic: it aggregates readily and forms amyloid fibrils, which is not a property you want in an injectable compound. Pramlintide, the first synthetic amylin analogue, solved this by substituting three amino acids, but it requires injection with every meal, which limits real-world use considerably. Cagrilintide takes a different engineering approach. It is fatty-acid acylated to extend its half-life to roughly one week, similar to the engineering behind semaglutide versus liraglutide. That single-weekly-dose profile is what makes it practical to combine with once-weekly semaglutide.

The mechanism difference from GLP-1 matters because GLP-1 receptor agonists produce tolerance through receptor downregulation over time, and the appetite suppression plateaus for many people. Amylin receptor pathways are a genuinely separate signal. Combining them has an additive or potentially synergistic effect that you would not get by simply increasing the semaglutide dose.

CagriSema trial results

REDEFINE 1: the headline numbers

The REDEFINE 1 trial was the pivotal Phase 3 study for CagriSema in adults with obesity or overweight without type 2 diabetes, running for 68 weeks. Participants lost approximately 22 to 25 percent of body weight on average with CagriSema, compared to roughly 15 percent on semaglutide 2.4 mg alone. The placebo arm lost approximately 2 to 3 percent.

Those numbers put CagriSema roughly in the same territory as the top end of the tirzepatide dose range (approximately 20 to 22 percent at 15 mg) and competitive with early Phase 2 retatrutide data. The important distinction is pathway: CagriSema achieves similar results through GLP-1 plus amylin rather than GLP-1 plus GIP plus glucagon.

REDEFINE 2: type 2 diabetes population

The type 2 diabetes cohort typically shows less absolute weight loss than a non-diabetic obesity population because metabolic baseline differences affect body composition response. REDEFINE 2 followed that pattern: meaningful weight reduction and glycaemic improvements, but the headline number is lower than REDEFINE 1. The glycaemic results were notable: the amylin pathway's direct effect on glucagon suppression and post-meal glucose adds a mechanism to the semaglutide GLP-1 effect that goes beyond weight loss alone.

Cagrilintide as monotherapy

Phase 2 monotherapy data showed roughly 10 to 11 percent weight loss at 2.4 mg weekly. That is a meaningful result for a single compound on a non-GLP-1 pathway, but the reason cagrilintide is genuinely interesting is the combination, not the monotherapy. The combination exceeds what either compound produces alone by enough to suggest the two pathways interact rather than just stack linearly.

Cagrilintide dosage protocols

The clinical trial escalation schedule is the reference point for research use. The slow ramp exists to reduce the GI side effects that are worst at higher concentrations during early exposure. Jumping straight to 2.4 mg would produce significantly more nausea than reaching the same dose after 20 weeks of escalation.

Injection technique. Subcutaneous, typically abdomen, thigh, or upper arm. Rotate sites each week. Standard insulin-syringe or pen technique. The reconstitution and injection protocols are the same as for any lyophilised research peptide. The injection guide covers the mechanics, and the reconstitution guide handles the prep steps.

No approved dose. Cagrilintide is still in Phase 3 trials and has no FDA-approved dosing. The above reflects what trial protocols used, not a clinical recommendation.

Cagrilintide vs tirzepatide vs retatrutide

Where does cagrilintide fit? As monotherapy it does not match these numbers, but that is not the intended use. CagriSema reaches 22 to 25 percent while using a pathway that does not overlap with GLP-1 mechanisms. For someone who has hit a plateau on semaglutide alone, adding an amylin-pathway compound represents a genuinely different option rather than a dose escalation of the same mechanism.

The deeper comparison question is whether CagriSema eventually competes with tirzepatide and retatrutide as an approved product, or whether it finds a more specific position in patients who are GLP-1 partial responders. That answer depends on FDA outcomes and Phase 3 completion, neither of which is resolved as of mid-2026. The tirzepatide vs retatrutide comparison covers the approved-vs-pipeline framing in more depth.

How the amylin pathway complements GLP-1

GLP-1 receptor agonists work primarily through appetite suppression driven by hypothalamic signalling and a degree of gastric motility reduction. The appetite suppression effect is real and accounts for most of the weight loss. But GLP-1 receptor downregulation over time is also real, which is why many people find their weight loss plateaus after several months of stable dosing.

Amylin does not signal through GLP-1 receptors. It acts through AMY1-3 receptors (combinations of calcitonin receptor with receptor activity-modifying proteins) and through direct area postrema signalling. The satiety signal is distinct in origin, which is the mechanistic reason why combining the two produces more effect than either alone. The gastric emptying delay from amylin adds to the GLP-1 mechanism rather than duplicating it, extending the post-meal satiety window further than either compound manages individually.

This is also why comparing the efficacy of CagriSema to tirzepatide by weight-loss percentage alone is somewhat reductive. The glycaemic effects, the composition of weight lost, and the durability of the effect may differ in ways that 68-week trial data does not yet fully characterise.

Cagrilintide side effects

The side effect profile is predictable from the mechanism. GI effects dominate, particularly during escalation, and are broadly similar to what the GLP-1 class produces because the two compounds share gastric emptying as a downstream effect.

• Nausea: The most commonly reported, peaking during escalation steps. Typically improves at each stable dose level before the next increase. Taking the injection before a smaller meal and staying adequately hydrated helps most people manage it.
• Vomiting: Less common than nausea but occurs, especially in weeks 5 through 12 of escalation. Some participants in the REDEFINE trials discontinued for this reason, at rates similar to semaglutide discontinuation from GI effects.
• Diarrhoea and constipation: Both appear in trial data. Gastric emptying changes can shift transit in either direction depending on individual baseline motility.
• Injection site reactions: Redness, minor swelling, and mild discomfort at the injection site. Rotating locations resolves most injection-site reactions.
• Heart rate increase: A mild elevation in resting heart rate was noted in trial data, consistent with amylin receptor pharmacology. Not as pronounced as seen with some GLP-1 agents but present as a signal to monitor.
• Headache and fatigue: Reported in a minority of participants, more common early in the escalation period.

The safety signals in REDEFINE trials did not surface anything novel or unexpected relative to what the GLP-1 class has already characterised. The amylin pathway does not add the pancreatitis or gallbladder signals that GLP-1 agents carry as labelled warnings, though that assessment will be updated as the full Phase 3 safety dataset is reviewed by regulatory bodies.

Long-term cardiovascular outcomes data does not yet exist for cagrilintide. The REDEFINE cardiovascular outcomes trial is ongoing. For more on GI side effect management in this compound class, the semaglutide side effects guide covers the shared elements of the GLP-1 side effect profile in detail.

Research sourcing and quality

Cagrilintide is a more complex molecule than small peptides like KPV or BPC-157, and synthesis quality matters more as a result. Fatty-acid acylation is not a commodity process. A vendor cutting corners on the acylation step produces a compound with a significantly shorter half-life than it should have, which means the weekly dosing schedule would not behave as expected.

What to verify:

• Certificate of analysis with HPLC purity at 98 percent or higher, matched to the specific lot number
• Mass spectrometry confirming correct molecular weight (cagrilintide: approximately 4030 Da)
• Confirmation that acylation is present and attached at the correct position
• Sterility and endotoxin testing for injectable compounds
• Third-party lab, not in-house self-certification

Storage follows standard lyophilised peptide rules: freezer for the powder, refrigerator after reconstitution, protected from light. The peptide storage guide covers stability windows in more detail.